Of the 2210 women with invasive breast cancer who enrolled in the CBCP between 2010 and 2019, 60 (2.7%) had ERLP/HER2-tumors with PR staining ≤ 10% tumors and 254 (11.5%) had TNBC (Figure 1). Here, ERBB2 is linked to invasive breast carcinoma.